Management of Upper Gastrointestinal Bleeding with Proton Pump Inhibitors

Evidence-Based Dosing Protocol

The American College of Gastroenterology recommends a high-dose pantoprazole regimen, consisting of an 80 mg IV bolus followed by an 8 mg/hour continuous infusion for 72 hours, to reduce rebleeding, need for surgery, and mortality in patients with upper GI bleeding 1, 2, 3
The standard high-dose PPI regimen is supported by the American College of Physicians and International Consensus Group with Grade A/1B evidence, representing the highest quality guideline recommendations 1, 2

The American College of Gastroenterology suggests that continuous infusion is critical to maintain gastric pH above 6, necessary for platelet aggregation and clot stability, thereby reducing rebleeding risk 1
The high-dose continuous infusion regimen has demonstrated reduced mortality (OR 0.56, 95% CI 0.34-0.94) 1
The high-dose continuous infusion regimen has also demonstrated reduced rebleeding rates (OR 0.43, 95% CI 0.29-0.63) 1
The high-dose continuous infusion regimen has shown decreased need for surgery compared to placebo or H2-receptor antagonists 1

The American College of Gastroenterology recommends starting the continuous infusion immediately, even before endoscopy is performed, with a weaker recommendation (Grade C/2B) but excellent safety profile and potential benefits 1, 2, 4
PPI therapy must never replace or delay urgent endoscopy, as it is adjunctive therapy only 1, 2

After completing the 72-hour IV infusion, the American College of Gastroenterology recommends transitioning to oral PPI 40 mg twice daily on days 4-14 1
Then, oral PPI 40 mg once daily from day 15 onward for 6-8 weeks total to allow complete mucosal healing 1, 2

The American College of Gastroenterology suggests testing for H. pylori and providing eradication therapy if positive, as this reduces recurrent bleeding risk 2, 4
Administering pre-endoscopy erythromycin enhances gastric visualization during endoscopy 1
The benefits of high-dose PPI regimen are most pronounced in patients with high-risk endoscopic stigmata (active bleeding, visible vessel, or adherent clot) 2, 3